Comparison of myelosuppression in patients receiving FCR and alemtuzumab: patients with baseline neutrophil count more than 103/μL
| Parameter . | Prophylaxis regimen, no. of patients/no. evaluable . | |
|---|---|---|
| Valganciclovir . | Valaciclovir . | |
| Neutrophils grade 3–4 | 9/14 (64%) | 4/7 (57%) |
| Platelets grade 3–4 | 6/10 (60%) | 5/5 (100%) |
| Median baseline platelet count | 161 × 109/L | 125 × 109/L |
| Parameter . | Prophylaxis regimen, no. of patients/no. evaluable . | |
|---|---|---|
| Valganciclovir . | Valaciclovir . | |
| Neutrophils grade 3–4 | 9/14 (64%) | 4/7 (57%) |
| Platelets grade 3–4 | 6/10 (60%) | 5/5 (100%) |
| Median baseline platelet count | 161 × 109/L | 125 × 109/L |